In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Angiotech's Life After Drug Eluting Stents

Executive Summary

Angiotech, best known for formulating the paclitaxel that goes on Boston Scientific's drug-eluting stent, has has signed two orthopedics deals; it's acquired NeuColl Inc., a private developer of collagen-based biomaterials for orthopedic applications and has also allied with Orthovita Inc., which will distribute Angiotech's hemostatic biomaterial in orthopedics markets. These, together with a string of other acquisitions in the past year, have diversified Angiotech into interventional cardiology, vascular surgery, anti-adhesion in gynecological surgery, and orthopedics--apparently unrelated fields. That represents a great deal of diversity for a mid-sized company with limited resources, but all of the areas share a common theme. Beyond the drug-eluting stent, Angiotech believes that potentially hundreds of large markets exist where drugs can improve the performance of devices.

Related Content


Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts